Summit Therapeutics
Watchlist
Summit Therapeutics - US Biotech Company Impresses With a Strong Pipeline, Licensing Deal With AstraZeneca Fuels Speculation!
Reading Time: 1 minute
Business drivers: Summit Therapeutics (SMMT) specializes in developing innovative drugs for the treatment of cancer and other serious diseases. One of the promising candidates in the portfolio is the compound Ivonescimab, a novel bi-specific antibody that is intended to significantly enhance the immune response against tumor cells by simultaneously inhibiting PD-1 (Programmed Cell Death Protein 1) and VEGF (Vascular Endothelial Growth Factor). Summit Therapeutics is collaborating with the pharmaceutical giant Pfizer, among others. On July...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
